Table 1 Demographics for all melanoma patients
From: Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma
Characteristics | All patients |
|---|---|
N = 307 | |
Age [Median (IQR)] | 64 (55–75) |
Sex | |
Female | 140 (46%) |
Male | 167 (54%) |
Race | |
Non-Hispanic White | 259 (84%) |
Non-Hispanic Black | 8 (3%) |
Hispanic | 14 (5%) |
Other | 22 (7%) |
Missing/Unknown | 4 (1%) |
Geographic location | |
US Sunbelt region, Spain, or Mexico | 81 (26%) |
US states outside of Sunbelt region or Canada | 225 (73%) |
Missing/Unknown | 1 (0%) |
Smoking status | |
Never | 179 (58%) |
Current or Former | 118 (38%) |
Missing/Unknown | 10 (3%) |
Obesity | |
Not obese | 200 (65%) |
Obese | 105 (34%) |
Missing/Unknown | 2 (1%) |
Comorbidities | |
Diabetes mellitus | 56 (18%) |
Pulmonary comorbidities | 56 (18%) |
Cardiovascular comorbidities | 69 (22%) |
Renal comorbidities | 38 (12%) |
Immunosuppressed | 44 (14%) |
Missing/Unknown | 2 (1%) |
ECOG Status | |
0 | 129 (42%) |
1 | 62 (20%) |
2 + | 28 (9%) |
Unknown | 87 (28%) |
Missing | 1 (0%) |
Cancer Status | |
Remission/NED | 168 (55%) |
Active, stable/responding | 70 (23%) |
Active, progressing | 37 (12%) |
Unknown | 32 (10%) |
Recent systemic cancer therapy | |
Systemic therapy in the last 3 months | 86 (28%) |
Cytotoxic Therapy | 11 (4%) |
Targeted Therapy | 32 (10%) |
Immunotherapy | 52 (17%) |
No systemic therapy in the last 3 months | 215 (70%) |
Missing/Unknown | 6 (2%) |
COVID-19 treatments | |
Low-dose steroids ever | |
Yes | 41 (13%) |
No | 256 (83%) |
Missing/Unknown | 10 (3%) |
High-dose steroids ever | |
Yes | 37 (12%) |
No | 254 (83%) |
Missing/Unknown | 16 (5%) |
Monoclonal antibodies | |
Yes | 10 (3%) |
No | 290 (94%) |
Missing/Unknown | 7 (2%) |
Timing of COVID diagnosis | |
Jan—Apr 2020 | 63 (21%) |
May—Aug 2020 | 102 (33%) |
Sep—Dec 2020 | 86 (28%) |
Jan—Apr 2021 | 32 (10%) |
May—Aug 2021 | 15 (5%) |
Sep—Dec 2021 | 9 (3%) |